BioAegis Therapeutics is Drug Discovery in United States that focus on infectious diseases business. Founded in 2011. They cover business area such as operator, inflammation, infectious disease, development, drug, plasma gelsolin, a key component, innate immunity, an immunotherapeutic approach, pathogen, hospital, treatment, a high likelihood.
2011
( 15 years old in 2026 )
Infectious Diseases
-
Commercialization Center for Innovative Technology
675 US Highway One
North Brunswick, NJ 08902
United States
Private
operatorinflammationinfectious diseasedevelopmentdrugplasma gelsolina key componentinnate immunityan immunotherapeutic approachpathogenhospitaltreatmenta high likelihood
* We use standard office opening hours in near BioAegis Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
BioAegis Therapeutics is Drug Discovery business from United States that founded in 2011 (15 years old in 2026), BioAegis Therapeutics business is focusing on Infectious Diseases.
BioAegis Therapeutics headquarter office and corporate office address is located in Commercialization Center for Innovative Technology 675 US Highway One North Brunswick, NJ 08902 United States.
BioAegis Therapeutics was founded in United States.
In 2026, BioAegis Therapeutics is currently focus on infectious diseases sector.
Above is snippet of Google Trends for "infectious diseases" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with BioAegis Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
